Study on extracellular matrix metalloproteinase inducer and human epidermal growth factor receptor‑2 protein expression in papillary thyroid carcinoma using a quantum dot‑based immunofluorescence technique

Tang,Tian; Zhang,Duan-Lian

doi:10.3892/etm.2015.2287

Study on extracellular matrix metalloproteinase inducer and human epidermal growth factor receptor‑2 protein expression in papillary thyroid carcinoma using a quantum dot‑based immunofluorescence technique

Authors:
- Tian Tang
- Duan-Lian Zhang
View Affiliations

Affiliations: Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: February 12, 2015 https://doi.org/10.3892/etm.2015.2287
Pages: 1331-1335

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the association of extracellular matrix metalloproteinase inducer (EMMPRIN) and human epidermal growth factor receptor (HER)‑2 protein expression in papillary thyroid carcinoma with lymph node metastasis (LNM), as well as the correlation between the two types of protein expression. A quantum dot‑based immunofluorescence technique was used to detect EMMPRIN and HER‑2 protein expression in 75 papillary thyroid carcinoma cases (including 70 cases of papillary thyroid carcinoma tissues and 5 cases of peri‑tumor tissues). The positive rate and expression of EMMPRIN and HER‑2 were compared and observed. The positive rate of EMMPRIN was 75.71% in papillary thyroid carcinoma tissues and 20.00% in peri‑tumor tissues (P<0.05). The positive rate of HER‑2 was 45.71% in papillary thyroid carcinoma tissues and 0% in peri‑tumor tissues (P>0.05). The expression of EMMPRIN and HER‑2 in papillary thyroid carcinoma was significantly associated with LNM (P<0.05). In addition, in the 70 papillary thyroid carcinoma tissues, the expression of EMMPRIN and HER‑2 was positively and significantly correlated. In conclusion, this study demonstrates that the co‑evolution of EMMPRIN and HER‑2 may promote the occurrence and development of papillary thyroid carcinoma and LNM.

View Figures

View References

1	Ito Y, Miyauchi A, Kobayashi K and Miya A: Prognosis and growth activity depend on patient age in clinical and subclinical papillary thyroid carcinoma. Endocr J. 61:205–213. 2014. View Article : Google Scholar
2	Dalberg K, Eriksson E, Enberg U, Kjellman M and Bäckdahl M: Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: Correlation with invasive growth of breast cancer. World J Surg. 24:334–340. 2000. View Article : Google Scholar : PubMed/NCBI
3	Meert AP, Martin B, Paesmans M, Berghmans T, Mascaux C, Verdebout JM, Delmotte P, Lafitte JJ and Sculier JP: The role of HER-2/neu expression on the survival of patients with lung cancer: A systematic review of the literature. Br J Cancer. 89:959–965. 2003. View Article : Google Scholar : PubMed/NCBI
4	Delellis RA, Lloyd RV, Heitx PU and Eng C: Pathology and Genetics of Tumors of Endocrine Organs. World Health Organization Classification of Tumours Lyon: pp. 73–76. 2004
5	Kramer MW, Merseburger AS, Hennenlotter J and Kuczyk M: Tissue microarrays in clinical urology - technical considerations. Scand J Urol Nephrol. 41:478–484. 2007. View Article : Google Scholar
6	Jawhar NM: Tissue microarray: A rapidly evolving diagnostic and research tool. Ann Saudi Med. 29:123–127. 2009. View Article : Google Scholar : PubMed/NCBI
7	Kallioniemi OP, Wagner U, Kononen J and Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 10:657–662. 2001. View Article : Google Scholar : PubMed/NCBI
8	Hall M, Kazakova I and Yao YM: High sensitivity immunoassays using particulate fluorescent labels. Anal Biochem. 272:165–170. 1999. View Article : Google Scholar : PubMed/NCBI
9	Hermanson GT: Bioconjugate Techniques. 2nd edition. Academic Press; London, UK: pp. 297–416. 1996, View Article : Google Scholar
10	Sienel W, Polzer B, Elshawi K, et al: Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Mod Pathol. 21:1130–1138. 2008. View Article : Google Scholar : PubMed/NCBI
11	Zheng HC, Takahashi H, Murai Y, et al: Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: A good marker for local invasion and prognosis. Br J Cancer. 95:1371–1378. 2006. View Article : Google Scholar : PubMed/NCBI
12	Quemener C, Gabison EE, Naïmi B, et al: Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res. 67:9–15. 2007. View Article : Google Scholar : PubMed/NCBI
13	Bougatef F, Quemener C, Kellouche S, et al: EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood. 114:5547–5556. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lu Q, Lv G, Kim A, Ha JM and Kim S: Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma. Oncol Lett. 5:201–207. 2013.
15	Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, Tsuneyama K and Takano Y: Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol. 60:273–277. 2007. View Article : Google Scholar
16	Chao WR, Lee MY, Lin WL, Chen CK, Lin JC, Koo CL, Sheu GT and Han CP: HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer. Hum Pathol. 45:810–816. 2014. View Article : Google Scholar : PubMed/NCBI
17	Brennan PJ, Kumagai T, Berezov A, Murali R and Greene MI: HER-2/neu: Mechanisms of dimerization/oligomerization. Oncogene. 19:6093–6101. 2000. View Article : Google Scholar
18	Lohrisch C and Piccart M: An overview of HER2. Semin Oncol. 28(Suppl 18): 3–11. 2001. View Article : Google Scholar
19	Ho VW, Leung K, Hsu A, et al: A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res. 71:4484–4493. 2011. View Article : Google Scholar : PubMed/NCBI
20	Debled M, Dalenc F, Mauriac L and Brain E: Medical treatments of endocrine-sensitive Her-2 negative breast cancers: A review. Bull Cancer. 98:655–670. 2011.(In French). PubMed/NCBI
21	Menashi S, Serova M, Ma L, Vignot S, Mourah S and Calvo F: Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res. 63:7575–7580. 2003.PubMed/NCBI
22	Auvinen P, Tammi R, Kosma VM, Sironen R, Soini Y, Mannermaa A, Tumelius R, Uljas E and Tammi M: Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer. 132:531–539. 2013. View Article : Google Scholar
23	Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K and Kortsaris A: The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Neoplasma. 55:113–121. 2008.PubMed/NCBI
24	Yang Q, Liu Y, Huang Y, Huang D, Li Y, Wu J and Duan M: Expression of COX-2, CD44v6 and CD147 and relationship with invasion and lymph node metastasis in hypopharyngeal squamous cell carcinoma. PLoS One. 8:e710482013. View Article : Google Scholar : PubMed/NCBI
25	Huang T, Chen MH, Wu MY and Wu XY: Correlation between expression of extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 and cervical lymph node metastasis of nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 122:210–215. 2013.PubMed/NCBI
26	Tan H, Ye K, Wang Z and Tang H: CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma. Transl Res. 152:143–149. 2008. View Article : Google Scholar : PubMed/NCBI
27	Suzuki S and Ishikawa K: Combined inhibition of EMMPRIN and epidermal growth factor receptor prevents the growth and migration of head and neck squamous cell carcinoma cells. Int J Oncol. 44:912–917. 2014.PubMed/NCBI
28	Gialeli Ch, Theocharis AD, Kletsas D, Tzanakakis GN and Karamanos NK: Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab. Invest New Drugs. 31:516–524. 2013. View Article : Google Scholar